Ahmedabad, Gujarat, India, April 2025 — Hemant Kumar has joined Cadila Pharmaceuticals Limited as President – Supply Chain & Procurement, bringing with him over three decades of global leadership experience in supply chain, logistics, procurement, and distribution across some of the world’s leading pharmaceutical companies. In this strategic role, Hemant will be responsible for end-to-end supply chain operations for both formulations and APIs, across domestic and international markets.
Prior to joining Cadila Pharmaceuticals, Hemant served as Group Vice President & Global Head – Integrated Supply Chain and Logistics at Glenmark Pharmaceuticals, where he oversaw operations across five continents. He was instrumental in managing demand and supply planning across 10 global manufacturing facilities and over 100 external manufacturing partners, servicing a $1.6 billion global commercial footprint.
Earlier in his career, Hemant held leadership roles at Mylan Laboratories as Vice President & Head of Regional Supply Chain & Logistics, and at SUN Pharma and Ranbaxy Laboratories, where he led major transformation and integration projects. At SUN-Ranbaxy, he directed central supply chain functions and played a key role in managing over 8,000 SKUs globally, along with the integration efforts following the merger.
His earlier work at Ranbaxy also included spearheading company-wide initiatives such as RISE (Ranbaxy Institutionalizing Simplicity and Excellence), covering areas like Supply Chain Management Excellence, Quality by Design, and Integrated Product Development. These efforts were undertaken in partnership with global consultancy firms and reflected Hemant’s strategic vision in building agile, responsive, and scalable supply chains.
With a proven track record in supply planning, procurement, logistics optimization, and systems implementation including SAP APO, Hemant’s appointment marks a pivotal leadership move for Cadila Pharmaceuticals as it strengthens its global supply operations. His vast expertise in global sourcing, transformation initiatives, and data-driven execution is expected to accelerate Cadila’s operational resilience and innovation-led growth.
Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Ltd., founded by Shri I.A. Modi, is one of India’s largest privately held pharmaceutical companies, with a global footprint spanning more than 100 countries. Headquartered in Ahmedabad, Gujarat, the company has been a pioneer in therapeutic innovation, manufacturing, and research for over seven decades. Cadila is present in more than 45 therapeutic areas, with a strong emphasis on cardiovascular, anti-infectives, gastrointestinal, and immunological segments. It operates USFDA-approved manufacturing facilities in India and Ethiopia and employs more than 300 scientists across its R&D divisions.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
